Clinical Trial Update: Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update reports final results from a Phase 2/3 study evaluating nab-paclitaxel with gemcitabine and carboplatin versus gemcitabine and carbop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (Abraxane) (nab-paclitaxel)

Snippet

Sponsor: Celgene | Conditions: Breast Tumor, Breast Cancer | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2018-03-08